Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autoimmune diabetes vaccine (Diamyd) - Diamyd Medical

Next Previous
Drug Profile

Autoimmune diabetes vaccine (Diamyd) - Diamyd Medical

Alternative Names: Antigen-based therapy (ABT) - Diamyd Medical; Diabetes-mellitus-vaccine-Diamyd-Medical; Diabetes-mellitus-vaccine-Diamyd-Therapeutics; Diamyd; GAD-65 - Diamyd Medical; GAD-Alum vaccine; GAD-Alum vaccine - Diamyd Medical; GAD-antigen therapy (Diamyd); Glutamate decarboxylase 2 - human, recombinant; rhGAD-65-Diamyd-Medical

Latest Information Update: 16 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Diamyd Medical
  • Developer Diamyd Medical AB; Linkoping University; Lund University; Norwegian university of science and technology; University of Alabama at Birmingham
  • Class Antihyperglycaemics; Diabetes mellitus vaccines; Recombinant proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Type 1 diabetes mellitus
  • Phase II Latent autoimmune diabetes in adults

Most Recent Events

  • 15 Feb 2024 Diamyd Medical receives Fast Track designation for Type 1 diabetes mellitus [Intralymphatic,Injection] (In adolescents, In children, In adults) in USA
  • 07 Dec 2023 Diamyd Medical has patent protection for precision medicine patent in South Korea
  • 20 Oct 2023 Efficacy and adverse events data from a phase I/II DIAGNODE-B trial in Type 1 diabetes mellitus released Diamyd Medical AB
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top